All Updates

All Updates

icon
Filter
Funding
Partnerships
3DBioFibR and PlantForm raise CAD 1.3 million to create dry-spun recombinant human collagen fibers
Bio-based Materials
Jan 18, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Bio-based Materials

Bio-based Materials

Jan 18, 2024

3DBioFibR and PlantForm raise CAD 1.3 million to create dry-spun recombinant human collagen fibers

Funding
Partnerships

  • 3DBioFibR Inc, a Halifax-based biomaterials developer, and PlantForm Corporation, a biopharmaceutical firm, have received CAD 1.3 million (~USD 966,000) from Next Generation Manufacturing Canada (NGen) to support one-third of their CAD 3.6 million (~USD 2.76 million) project, with the remaining expenses covered by the companies.

  • The funding will be used to support a project to create the first large-scale dry spinning of recombinant human collagen fibers, which will be integrated into the pharmaceutical and biomedical sectors, among others.

  • PlantForm and 3DBioFibR aim to reproduce natural collagen fibers to match or surpass their natural strength, a significant stride for the biomaterial and tissue engineering field. Presently, 3DBioFibR leads in creating biomaterials for tissue regeneration, whereas PlantForm focuses on the inexpensive production of high-value vaccines and protein-based drugs via the vivoXPRESS plant-based manufacturing system.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.